Pap smear upgrade? DNA test could spot hidden uterine cancer

NCT ID NCT07298707

Not yet recruiting Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will test a new molecular test called CISENDO, which looks at DNA methylation in cells from a routine cervical smear. The goal is to see if it can accurately detect endometrial cancer or precancerous lesions in women at medium-to-high risk. Researchers will compare the test results to standard hysteroscopy with biopsy. If accurate, this could offer a less invasive way to screen for and monitor endometrial cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CISENDO test (DNA methylation test on cervical cytology samples)
What this could lead to: If successful, this could provide a simple, non-invasive screening test for endometrial cancer, reducing the need for invasive procedures like hysteroscopy.
What could go wrong: This is an early observational study, not a treatment trial. The test may not be accurate enough to replace current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL SMEARS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical endometrial hyperplasia endometrial cancer Endometrial Hyperplasia endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL SMEARS DNA METHYLATION EARLY DETECTION OF CANCER ENDOMETRIAL HYPERPLASIA ENDOMETRIAL NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.